Metformin improves renal injury of MRL/lpr lupus-prone mice via the AMPK/STAT3 pathway

• Published in: Lupus science & medicine Vol. 9; no. 1; p. e000611
• Main Authors: Chen, Xiao-cui, Wu, Dan, Wu, Hong-luan, Li, Hui-yuan, Yang, Chen, Su, Hong-yong, Liu, Ze-jian, Huang, Xiao-rong, Lu, Xing, Huang, Li-feng, Zhu, Shao-ping, Pan, Qing-jun, An, Ning, Liu, Hua-feng
• Format: Journal Article
• Language: English
• Published: England Lupus Foundation of America 01.04.2022; BMJ Publishing Group LTD; BMJ Publishing Group
• Series: Original research
• Subjects: AMP-Activated Protein Kinases - metabolism; AMP-Activated Protein Kinases - pharmacology; Animals; Antidiabetics; Apoptosis; Creatinine; Humans; Inflammation; Kidney - metabolism; Kidneys; Kinases; Laboratory animals; Lipopolysaccharides - metabolism; Lipopolysaccharides - pharmacology; Lipopolysaccharides - therapeutic use; Lupus; Lupus Erythematosus, Systemic; Lupus Erythematosus, Systemic - complications; Lupus Erythematosus, Systemic - drug therapy; Lupus Nephritis; Lupus Nephritis - complications; Lupus Nephritis - drug therapy; Metformin - pharmacology; Metformin - therapeutic use; Mice; Mice, Inbred MRL lpr; Monoclonal antibodies; NLR Family, Pyrin Domain-Containing 3 Protein - metabolism; Proteins; Signal Transduction - physiology; STAT3 Transcription Factor - metabolism; STAT3 Transcription Factor - pharmacology; STAT3 Transcription Factor - therapeutic use; Therapeutics; Tumor Necrosis Factor-alpha - metabolism; Tumor Necrosis Factor-alpha - pharmacology; Tumor Necrosis Factor-alpha - therapeutic use; Tumor necrosis factor-TNF; United States > US; China; Japan; Lupus Nephritis; Lupus Erythematosus, Systemic; Therapeutics

ObjectiveLupus nephritis (LN) is a major complication and cause of death among patients with SLE. This research used in vivo and in vitro experiments to explore the therapeutic potential of metformin in kidney injury from LN-induced inflammation.MethodsIn vivo study, 8-week-old MRL/MpJ-Faslpr/J (MRL...